Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy
- PMID: 24756303
- DOI: 10.1124/jpet.113.211771
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy
Abstract
Multiple sclerosis (MS) is an autoimmune-inflammatory disease of the central nervous system (CNS) with prominent demyelination and axonal injury. While most MS therapies target the immunologic response, there is a large unmet need for treatments that can promote CNS repair. LINGO-1 (leucine-rich repeat and Ig-containing Nogo receptor interacting protein-1) is a membrane protein selectively expressed in the CNS that suppresses myelination, preventing the repair of damaged axons. We are investigating LINGO-1 antagonist antibodies that lead to remyelination as a new paradigm for treatment of individuals with MS. The anti-LINGO-1 Li81 antibody,BIIB033, is currently in clinical trials and is the first MS treatment targeting CNS repair. Here, to elucidate the mechanism of action of the antibody, we solved the crystal structure of the LINGO-1-Li81 Fab complex and used biochemical and functional studies to investigate structure-function relationships. Li81 binds to the convex surface of the leucine-rich repeat domain of LINGO-1 within repeats 4-8. Fab binding blocks contact points used in the oligomerization of LINGO-1 and produces a stable complex containing two copies each of LINGO-1 and Fab that results from a rearrangement of contacts stabilizing the quaternary structure of LINGO-1. The formation of the LINGO-1-Li81 Fab complex masks functional epitopes within the Ig domain of LINGO-1 that are important for its biologic activity in oligodendrocyte differentiation. These studies provide new insights into the structure and biology of LINGO-1 and how Li81 monoclonal antibody can block its function.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.
Similar articles
-
Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site.MAbs. 2020 Jan-Dec;12(1):1713648. doi: 10.1080/19420862.2020.1713648. MAbs. 2020. PMID: 31928294 Free PMC article.
-
Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration.J Pharmacol Exp Ther. 2011 Nov;339(2):519-29. doi: 10.1124/jpet.111.183483. Epub 2011 Aug 1. J Pharmacol Exp Ther. 2011. PMID: 21807883
-
Knockdown of Lingo1b protein promotes myelination and oligodendrocyte differentiation in zebrafish.Exp Neurol. 2014 Jan;251:72-83. doi: 10.1016/j.expneurol.2013.11.012. Epub 2013 Nov 18. Exp Neurol. 2014. PMID: 24262204
-
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.Expert Opin Biol Ther. 2008 Oct;8(10):1561-70. doi: 10.1517/14712598.8.10.1561. Expert Opin Biol Ther. 2008. PMID: 18774923 Review.
-
Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration.Int J Mol Sci. 2023 Feb 24;24(5):4479. doi: 10.3390/ijms24054479. Int J Mol Sci. 2023. PMID: 36901909 Free PMC article. Review.
Cited by
-
Effect of retinoic acid on expression of LINGO-1 and neural regeneration after cerebral ischemia.J Huazhong Univ Sci Technolog Med Sci. 2015 Feb;35(1):54-57. doi: 10.1007/s11596-015-1388-3. Epub 2015 Feb 12. J Huazhong Univ Sci Technolog Med Sci. 2015. PMID: 25673193
-
Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site.MAbs. 2020 Jan-Dec;12(1):1713648. doi: 10.1080/19420862.2020.1713648. MAbs. 2020. PMID: 31928294 Free PMC article.
-
Inhibition of LINGO1 as a therapeutic target to promote axonal regeneration and repair for neurological disorders.3 Biotech. 2023 Nov;13(11):372. doi: 10.1007/s13205-023-03789-4. Epub 2023 Oct 16. 3 Biotech. 2023. PMID: 37854938 Free PMC article.
-
Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration.Fluids Barriers CNS. 2018 Mar 20;15(1):10. doi: 10.1186/s12987-018-0093-6. Fluids Barriers CNS. 2018. PMID: 29558954 Free PMC article.
-
Biomaterial Approaches to Enhancing Neurorestoration after Spinal Cord Injury: Strategies for Overcoming Inherent Biological Obstacles.Biomed Res Int. 2015;2015:752572. doi: 10.1155/2015/752572. Epub 2015 Sep 27. Biomed Res Int. 2015. PMID: 26491685 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials